UnknownPhase 2NCT02997371
IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
Studying Moderate and severe traumatic brain injury
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Adel Helmy
- Principal Investigator
- Adel Helmy, MA, MB BChir, FRCS, PhDUniversity of Cambridge
- Intervention
- Anakinra Prefilled Syringe(drug)
- Enrollment
- 60 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2017 – 2021
Study locations (1)
- Cambridge University Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom
Collaborators
Cambridge University Hospitals NHS Foundation Trust
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02997371 on ClinicalTrials.govOther trials for Moderate and severe traumatic brain injury
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06866691Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamideWake Forest University Health Sciences
- RECRUITINGNANCT06241482Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical CareShanghai 6th People's Hospital
- RECRUITINGPHASE1, PHASE2NCT06282965Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain InjuryUniversity of Arizona
- RECRUITINGPHASE1NCT05716048Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain InjuryKessler Foundation
- ACTIVE NOT RECRUITINGNANCT05636020Intervention to Change Affect Recognition and EmpathyIndiana University
See all trials for Moderate and severe traumatic brain injury →